Core Insights - Lymphoma is the 10th most common cancer globally and has the fastest-growing incidence rate among malignant tumors, with approximately 100,000 new cases annually in China, over 50% of which are in individuals aged 60 and above [1][2] - The Chinese government has made significant progress in lymphoma diagnosis, treatment guidelines, and quality control measures, including the establishment of pilot programs for standardized treatment [1][4] - The approval of innovative drugs, such as tanzimab and lenalidomide for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL), marks a significant advancement in lymphoma treatment options [2][3] Industry Developments - The National Medical Products Administration conditionally approved tanzimab for adult patients with relapsed or refractory follicular lymphoma in November 2022, and its combination therapy for DLBCL was approved in May 2023 [2][3] - Clinical studies show promising results for tanzimab, with an overall response rate (ORR) of 57.5% and a complete response (CR) rate of 41.3% in global studies, while Chinese patients showed an ORR of 73.1% [3] - The 2023 "Healthy China Action - Cancer Prevention and Control Implementation Plan" aims to enhance cancer prevention and treatment capabilities, targeting a 5-year survival rate of 46.6% by 2030 [4][5]
中新健康丨淋巴瘤诊疗加速突破：创新药与规范诊疗共筑健康防线